OPN-2853 is under clinical development by Opna Bio and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OPN-2853’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PLX-2853 is under development for the treatment of myelofibrosis, solid tumors such as small-cell lung cancer, ovarian clear cell carcinoma (OCCC), uveal melanoma, relapsed and refractory acute myeloid leukemia, relapsed and refractory myelodysplastic syndrome, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma. The drug candidate is administered through the oral route. The drug candidate acts by targeting bromodomain-containing protein 4.
It was also under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC), cervical cancer, vaginal cancer, vulvar cancer, uterine cancer, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer..
Opna Bio overview
Opna Bio is a clinical-stage biopharmaceutical company focuses on the development and discovery of novel oncology therapeutics. Opna Bio is headquartered in Vaud, Switzerland.
For a complete picture of OPN-2853’s drug-specific PTSR and LoA scores, buy the report here.